{{Drugbox
| verifiedrevid = 451552022
| IUPAC_name = [(''N''-(2-amino-2-methylpropyl)-2-''cis''-dispiro(adamantane-2,3'-[1,2,4]trioxolane-5',1"-cyclohexan)-4"-yl]acetamide
| image = Arterolane.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 664338-39-0
| ATC_prefix = P01
| ATC_suffix = BX02
| ATC_supplemental = (combination with [[piperaquine]])
| PubChem = 10475633
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 25069705
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3N1TN351VB

<!--Chemical data-->
| C=22 | H=36 | N=2 | O=4
| molecular_weight = 392.531 g/mol
| smiles = C2C1CC5CC2CC(C5)C1(O3)OOC3(CC4)CCC4CC(=O)NCC(C)(C)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C22H36N2O4/c1-20(2,23)13-24-19(25)12-14-3-5-21(6-4-14)26-22(28-27-21)17-8-15-7-16(10-17)11-18(22)9-15/h14-18H,3-13,23H2,1-2H3,(H,24,25)/t14-,15-,16+,17-,18+,21+,22-
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VXYZBLXGCYNIHP-SSPKTAKCSA-N
}}

'''Arterolane''', also known as '''OZ277''' or '''RBx 11160''', is a substance that was tested for [[antimalarial drug|antimalarial]] activity<ref>{{cite journal |doi= 10.1021/jm901473s |title= The Structure−Activity Relationship of the Antimalarial Ozonide Arterolane (OZ277) |year= 2010 |last1= Dong |first1= Yuxiang |last2= Wittlin |first2= Sergio |last3= Sriraghavan |first3= Kamaraj |last4= Chollet |first4= Jacques |last5= Charman |first5= Susan A. |last6= Charman |first6= William N. |last7= Scheurer |first7= Christian |last8= Urwyler |first8= Heinrich |last9= Santo Tomas |first9= Josefina |last10= Snyder |first10= Christopher |last11= Creek |first11= Darren J. |last12= Morizzi |first12= Julia |last13= Koltun |first13= Maria |last14= Matile |first14= Hugues |last15= Wang |first15= Xiaofang |last16= Padmanilayam |first16= Maniyan |last17= Tang |first17= Yuanqing |last18= Dorn |first18= Arnulf |last19= Brun |first19= Reto |last20= Vennerstrom |first20= Jonathan L. |journal= Journal of Medicinal Chemistry |volume= 53 |pages= 481–91 |pmid= 19924861 |issue= 1 |display-authors= 8}}</ref> by [[Ranbaxy Laboratories]].<ref name=livemint>[http://www.livemint.com/2007/09/21011423/Blow-to-Ranbaxy-drugresearch.html Blow to Ranbaxy drug research plans] at LiveMint.com, Sep 21 2007</ref> It was discovered by US and European scientists who were coordinated by the [[Medicines for Malaria Venture]] (MMV).<ref>{{cite journal |doi= 10.1038/nature02779 |title= Identification of an antimalarial synthetic trioxolane drug development candidate |year= 2004 |last1= Vennerstrom |first1= Jonathan L. |last2= Arbe-Barnes |first2= Sarah |last3= Brun |first3= Reto |last4= Charman |first4= Susan A. |last5= Chiu |first5= Francis C. K. |last6= Chollet |first6= Jacques |last7= Dong |first7= Yuxiang |last8= Dorn |first8= Arnulf |last9= Hunziker |first9= Daniel |last10= Matile |first10= Hugues |last11= McIntosh |first11= Kylie |last12= Padmanilayam |first12= Maniyan |last13= Santo Tomas |first13= Josefina |last14= Scheurer |first14= Christian |last15= Scorneaux |first15= Bernard |last16= Tang |first16= Yuanqing |last17= Urwyler |first17= Heinrich |last18= Wittlin |first18= Sergio |last19= Charman |first19= William N. |journal= Nature |volume= 430 |issue= 7002 |pages= 900–4 |pmid= 15318224 |display-authors= 8}}</ref> Its molecular structure is uncommon for pharmacological compounds in that it has both a [[ozonide]] (trioxolane) group and an [[adamantane]] substituent.<ref>[http://blogs.sciencemag.org/pipeline/archives/2009/11/23/ozonides_as_drugs_what_will_they_think_of_next ''In the Pipeline'': "Ozonides As Drugs: What Will They Think Of Next?"], by Derek Lowe; published November 23, 2009; retrieved November 17, 2015; at Sciencemag.org</ref>

Initial results were disappointing, and in 2007 MMV withdrew support, after having invested $20M in the research;<ref name=launch/> Ranbaxy said at the time that it intended to continue developing the drug combination on its own.<ref name=livemint/> Ranbaxy started a [[Clinical trial#Phase II|Phase II clinical trial]] of arterolane, in combination with [[piperaquine]] in 2009 that published in 2015.<ref>India Clinical trials registry [http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=734&EncHid=&modid=&compid=%27,%27734det%27 CTRI/2009/091/000531]</ref><ref>Toure OA et al. Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study. Malar J. 2015 Nov 25;14(1):469. Clinical Trial Registry India: CTRI/2009/091/000531. {{PMID|26608469}} [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660726/ PMC4660726]</ref>

In 2012, Ranbaxy obtained approval to market the arterolane/piperaquine [[combination drug]] in India, under the brand name Synriam,<ref name=launch>Akshat Rathi for Chemistry World. 3 May 2012 [http://www.rsc.org/chemistryworld/2012/05/ranbaxy-launches-new-anti-malarial-synriam Ranbaxy launches new anti-malarial Synriam]</ref> and in 2014 received approval to market it in Nigeria, Uganda, Senegal, Cameroon, Guinea, Kenya and Ivory Coast; it had already received approval in Uganda.<ref>Staff, Business Standard. December 16, 2014 [http://www.business-standard.com/content/b2b-pharma/ranbaxy-receives-approval-for-malaria-drug-synriam-from-7-african-countries-114121700050_1.html Ranbaxy receives approval for malaria drug Synriam from 7 African countries]</ref>

==References==
{{reflist}}

{{Antimalarials}}

[[Category:Antimalarial agents]]
[[Category:Adamantanes]]
[[Category:Organic peroxides]]
[[Category:Spiro compounds]]


{{antiinfective-drug-stub}}